Enhertu, a collaboration drug by AstraZeneca and Daiichi, has been approved by the European Union for breast cancer treatment.

The approval was announced on Tuesday, for adult patients with an aggressive form of breast cancer.

AstraZeneca said that Enhertu could be used as a monotherapy in cases with unresectable or metastatic HER2-positive breast cancer.

The treatment was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The European Medicines Agency (EMA) gave its endorsement late in June.

EMA said Enhertu was effective at shrinking the tumour in patients with metastatic breast cancer or breast cancer that could not be removed by surgery.